I-MAB (IMAB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
I-Mab, a U.S.-based global biotech firm focusing on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP as its independent auditor for fiscal year 2024. This move is part of I-Mab’s strategic shift to reinforce its presence as a U.S. biotech entity, with no reported issues from the previous auditor. The company leaders express confidence in PwC’s alignment with shareholder interests and the firm’s capabilities to support I-Mab’s long-term growth objectives.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.